Connect with us

Naija News

Nigeria reveals drug they use in treating coronavirus

Ehanire

By Comrade Nnadi Goodluck

Get Federal Government Loan for Business Startup => See Here!

The Nigerian Government has finally revealed the drug the use in curing coronavirus patients.

This was disclosed during a press briefing on Tuesday by the Minister of Health, Osagie Ehanire.

The Minister revealed that Nigeria is currently using Remdesivir, an antiretroviral drug, in treating COVID-19 patients.

He said: “We have been using Remdesivir, we have tried that in Lagos too.

“So, we have tried the antiretroviral drug to see what effect it has.”

Osagie added that Nigeria has now moved from disease importation to community spread.

Also Read:  List of 10 Major Allegations Against EFCC Chairman, Ibrahim Magu

This revelation by the minister is coming barely four days after the US Food and Drug Administration (FDA) approved emergency use of Remdesivir, for treatment of the disease. The emergency FDA authorisation is not the same as formal approval, which requires a higher level of review.

The US National Institute of Health said the drug proved effective against the new coronavirus disease.

Remdesivir is originally a drug developed as a potential treatment for Ebola. It is produced by Gilead pharmaceutical company.

The drug is said to only interfere with the genome of coronavirus, disrupting its ability to replicate.

According to reports in UK, the drug has a 10-day dosing duration for patients on ventilators and five days for patients who are not.

Share this post

Continue Reading
You may also like...
1 Comment

1 Comment

  1. Ugopros

    May 5, 2020 at 10:01 pm

    Keep the fire burning my brother, the hacklord. One day, nations will come to your rising.

Leave a Reply

Your email address will not be published. Required fields are marked *

More in Naija News

Advertisement

Recent Posts

Subscribe to Our Newsletter

Enter your email address to SUBSCRIBE for FREE to this blog and receive notifications of new posts by email.

Join 7,751 other subscribers
To Top